Oral and Topical Tranexamic Acid for the Treatment of Melasma

• Status: Unknown status
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Tranexamic acid has been used for treating melasma due to its effect on decreasing the activity of tyrosinase and melanogenesis. This 3-arm clinical trial will asess the efficacy and safety of oral and topical tranexamic acid as monotherapy compared with topical hydroquinone for 12 weeks in adults with melasma. The primary outcome will be the percentage of reduction at 12-week period of mMASI and melanin index. The incidence of adverse effects will be reported at weeks 4, 8 and 12.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centro Dermatológico Dr. Ladislao de la Pascua
• Treatments: Hydroquinone; Tranexamic Acid

Criteria

Inclusion Criteria:

• Age older than 18 years

• Moderate to severe melasma

• History of multiple topical depigmenting treatments and use of photoprotection, with subjective improvement less than 50% or mMASI <50% reported by the dermatologist after one year of treatment.

Exclusion Criteria:

• Pregnancy

• Hormonal contraception

• Lactation

• Treatment with hydroquinone or tranexamic acid at the time of the study or in the last 3 months

• Endocrinology diseases

• Hormone replacement therapy

• Family or personal history of one of the following: autoimmune disorders, coagulation disorders, chronic venous insufficiency, heart diseases, retinopathies, kidney disorders

• Mental disability